Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center and Professor of Obstetrics and Gynecology at Florida International University, shared a post on LinkedIn about a recent paper he co-authored with colleagues published in Clinical Cancer Research:
“GLP-1 Receptor Agonists (Ozempic, Mounjaro, Zepbound) are changing the world.
I’m convinced it will help prevent and treat endometrial cancer. This review discusses this gamechanger.”
Title: Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities
Authors: Vivek Podder, Robert L. Coleman, Andrea R. Hagemann, Priya Singhania, Matthew A. Powell, Thomas J. Herzog, Brian M. Slomovitz
Read the Full Article in Clinical Cancer Research.
More posts featuring Brian Slomovitz on OncoDaily.